Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals is a vertically integrated pharmaceutical company committed to deliver high-quality healthcare access to patients across the world.(Source : 201903 Annual Report Page No: 2)
Market Cap:
10,440
Cr.
Current Price:
553.85
52 weeks High / Low
631.70 / 435.10
Book Value:
157.13
Stock P/E:
15.16
Dividend Yield:
0.99
%
ROCE:
22.58
%
ROE:
23.58
%
Sales Growth (3Yrs):
7.51
%
Listed on
BSE and NSE
Company Website
Face Value:
2.00
Pros:
Company has a good return on equity (ROE) track record: 3 Years ROE 22.21%
Company has been maintaining a healthy dividend payout of 18.24%
Cons:
Company might be capitalizing the interest cost
Dec 2016
Mar 2017
Jun 2017
Sep 2017
Dec 2017
Mar 2018
Jun 2018
Sep 2018
Dec 2018
Mar 2019
Jun 2019
Sep 2019
Sales
777
741
648
789
840
853
863
1,127
1,018
927
949
1,241
Expenses
632
606
547
610
652
680
712
825
776
749
724
895
Operating Profit
145
135
101
179
188
173
151
302
242
178
225
346
OPM %
19%
18%
16%
23%
22%
20%
18%
27%
24%
19%
24%
28%
Other Income
0
0
0
8
0
1
0
2
4
3
-30
0
Interest
1
2
1
0
1
1
2
6
6
5
5
7
Depreciation
21
22
22
26
26
32
28
29
29
30
35
36
Profit before tax
124
112
79
161
161
141
122
270
211
146
155
303
Tax %
32%
15%
20%
23%
19%
27%
26%
26%
19%
10%
23%
17%
Net Profit
87
93
67
122
131
94
90
200
170
124
124
246
EPS in Rs
4.59
4.94
3.54
6.45
6.93
4.98
4.80
10.61
9.01
6.58
6.56
13.06
Notes
Notes
Notes
Notes
Notes
Notes
Notes
Notes
Notes
Notes
Notes
Notes
Mar 2011
Mar 2012
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
TTM
Sales
1,202
1,465
1,520
1,863
2,056
3,166
3,105
3,131
3,935
4,135
Expenses
1,042
1,246
1,268
1,506
1,653
2,159
2,489
2,488
3,061
3,144
Operating Profit
160
219
252
358
403
1,007
616
643
874
991
OPM %
13%
15%
17%
19%
20%
32%
20%
21%
22%
24%
Other Income
4
13
4
4
4
7
1
7
9
-22
Interest
28
38
15
10
4
5
5
3
18
23
Depreciation
30
34
35
40
44
72
83
105
115
130
Profit before tax
107
161
206
311
359
936
529
541
749
815
Tax %
20%
19%
20%
24%
21%
23%
23%
22%
21%
Net Profit
85
130
165
236
283
720
403
413
584
664
EPS in Rs
6.68
8.34
11.98
14.30
38.20
21.39
21.89
31.00
35.21
Dividend Payout %
6%
20%
29%
24%
23%
9%
19%
18%
18%
* Sales is net of excise duty and discounts
Compounded Sales Growth
10 Years: %
5 Years: 16.13%
3 Years: 7.51%
TTM: 12.27%
Compounded Profit Growth
10 Years: %
5 Years: 19.85%
3 Years: -6.84%
TTM: 33.70%
Stock Price CAGR
10 Years: %
5 Years: 5.01%
3 Years: -4.61%
1 Year: -10.37%
Return on Equity
10 Years: %
5 Years: 28.88%
3 Years: 22.21%
Last Year: 23.58%
Mar 2011
Mar 2012
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Sep 2019
Share Capital
38
38
38
38
38
38
38
38
38
38
Reserves
259
357
465
638
847
1,560
1,865
2,182
2,681
2,924
Borrowings
328
353
187
109
264
114
89
708
1,128
1,232
Other Liabilities
270
324
375
449
509
741
754
1,096
1,053
1,413
Total Liabilities
868
1,071
1,064
1,234
1,657
2,452
2,745
4,024
4,900
5,608
Fixed Assets
272
268
344
397
547
708
799
993
1,158
1,491
CWIP
26
58
32
21
83
93
396
1,010
1,551
1,623
Investments
3
3
3
3
2
87
50
42
49
17
Other Assets
566
742
685
813
1,025
1,565
1,499
1,979
2,141
2,476
Total Assets
868
1,071
1,064
1,234
1,657
2,452
2,745
4,024
4,900
5,608
Mar 2011
Mar 2012
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
Cash from Operating Activity
95
142
265
240
172
948
329
312
812
Cash from Investing Activity
-57
-56
-67
-81
-256
-307
-486
-884
-756
Cash from Financing Activity
-47
-45
-229
-151
87
-224
-129
503
59
Net Cash Flow
-9
41
-31
8
3
417
-286
-69
115
Mar 2011
Mar 2012
Mar 2013
Mar 2014
Mar 2015
Mar 2016
Mar 2017
Mar 2018
Mar 2019
ROCE %
29%
31%
44%
38%
66%
29%
22%
23%
Debtor Days
61
50
56
54
64
40
40
61
45
Inventory Turnover
6.13
5.79
6.45
5.93
6.65
5.16
4.58
4.63